Navigation Links
Planet Technologies Announces Completion of Antigen Laboratories Acquisition

RIDGEFIELD, Conn. and LIBERTY, Mo., Nov. 9 /PRNewswire-FirstCall/ -- Planet Technologies, Inc. (Nasdaq: PLNT), a specialty pharmaceutical company focused on providing products for allergy and asthma sufferers, today announced that it has completed the acquisition of Antigen Laboratories, Inc. (Antigen), a privately-held FDA licensed manufacturer of allergenic extracts for immunotherapy.

"As announced in September, the acquisition of Antigen's allergenic extract immunotherapy business complements our existing allergen avoidance product business. The Antigen transaction continues to deliver on our strategy to acquire and build specialty allergy businesses, focused on marketing value-added products to allergy sufferers through allergy-related physicians in the United States," said Ed Steube, Chief Executive Officer and President of Planet.

Antigen will operate as a wholly owned subsidiary of Planet. Physicians use Antigen's allergenic extracts for immunotherapy, which historically have been administered to patients in controlled doses by subcutaneous injections ("SCIT"). Antigen provides allergenic extracts to over 1,500 physicians in the United States annually.

Importantly, upon completion of the acquisition, the company intends to commence a sublingual immunotherapy ("SLIT") clinical development program. SLIT is the administration of immunotherapy through drops of allergenic extract being placed under the tongue, versus the traditional SCIT route of administration. The company believes that an FDA-approved SLIT product will substantially expand the U.S. market for allergen immunotherapy, as allergy-related physicians will have the enhanced option of offering either SCIT or SLIT based immunotherapy for their patients.

"We also are pleased to announce that the company completed a private placement of approximately $19.9 million of its preferred stock. The financing was led by Aisling Capital, a leading private equity health care investor, which supplied capital to fund the acquisition, the prospective costs associated with the SLIT clinical development and regulatory approval program, capacity expansion at Antigen and incremental working capital," said Mr. Steube. "We look forward to continuing to execute our strategy, working closely with Aisling Capital to build our position as a market leader." When convertible, the preferred stock will be convertible into common stock at the conversion price of $2.25 per common share, subject to adjust upon the occurrence of certain events.

As part of the preferred stock financing, the company agreed to file a Form 15 with the SEC to deregister the company common stock under Section 12 of the Security Exchange Act of 1934. As a result, once filed, the company will no longer file annual or quarterly reports with the SEC and the Company's common stock will likely stop trading on the OTC Bulletin Board. The shares frequently do not trade and the average daily trading volume has recently been below the 200 shares per day at prices ranging from $1 to $5 per share. The infrequency of trading and wide fluctuation in prices has led management to believe the company would be better situated for future opportunities as a private, non-reporting company.

Concurrently with the closing of the acquisition of Antigen and preferred stock financing, Ellen Preston, Eric Freedus, H. Mac Busby, Mike Trinkle and Michael Walsh agreed to step down as directors of Planet. Tom Willoughby, the President of Antigen Laboratories, Inc., and Andrew Schiff and Brett Zbar, both affiliated with Aisling Capital were appointed to the Board of Directors. "We thank very much our former directors for their dedicated services and are pleased Tom, Andrew and Brett have agreed to join the Planet Board, "said Ed Steube.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Planet undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Planet's business.


Planet Technologies

Edward Steube

Chief Executive Officer

(203) 438-9580

SOURCE Planet Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Healthy planet, places and people at risk
3. Venture Health Group Selects Planet DDS Web-based Practice Management Software
4. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
5. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
6. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
7. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
8. Advanced technologies aim to transform the coaching of top athletes
9. Global Med Technologies(R) Extends Its Worldwide Outreach
10. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
11. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Trustify is ... in Washington, DC, hosted by Becky’s Fund, an organization dedicated to ending domestic violence. ... and control back to battered victims and survivors of domestic violence. Trustify is also ...
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday ... to NASDAQ to educate the personnel on spinal decompression therapy and offer his ... a nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is ...
(Date:12/1/2015)... , ... December 01, 2015 , ... The Multiple System ... awareness and funds for Multiple System Atrophy (MSA) research, timed today to coincide with ... many things from patients including their ability to work and be productive, to do ...
(Date:12/1/2015)... ... December 01, 2015 , ... The North American Meat ... that meat and poultry play in a healthy, balanced diet. , includes ... visitors can check their “meat IQ,” a section offering straight talk on controversies, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VERONA, Virginia , 1 de diciembre ... líder en tecnología para cuchillas de precisión, ... un programa de identidad de marca. El ... en el diseño y la ingeniería de ... toda la diferencia". ...
(Date:12/1/2015)... , Dec. 1, 2015 During the ... San Francisco, CA , Medinol ... the coronary marketplace. During a satellite symposium, "The ... Design to Minimize Restenosis", a renowned physician panel ... Medinol NIRxcell™ CoCr Coronary Stent System and the ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
Breaking Medicine Technology: